|
|
|
|
|
|
|
|
|
News | News By Subject |
News By Date | Search News
|
|
|
Print
Email
Immunomedics, Inc. (IMMU) Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma
6/13/2012 9:31:36 AM
MIAMI BEACH, Fla., June 13, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported initial clinical experience with a combination of epratuzumab, the Company's humanized anti-CD22 antibody, labeled with the radioisotope, yttrium-90 (90Y), and veltuzumab, the Company's humanized anti-CD20 antibody, in patients with relapsed aggressive non-Hodgkin lymphoma (NHL).
|
Read Article at |
Related Companies |
News Categories |
|
|
|
|
|
|
|
|
|
|
|
|
|
|